ARCHIVES

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

This article is from The Cancer Letter archive.

Vol. 13 No. 15 | April 10, 1987

Download PDF Visit The Full Archive

Related Articles

Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.

July 13, 2007

STAR Begins: Critics of Trial Call For Including A Placebo Arm

June 4, 1999

California To Help Uninsured Get Prostate Cancer Therapy.

July 13, 2001

IOM, NCI Clash Over Proposed Change in Tabulating Minority Research

January 22, 1999

ASCO Highlights Seven of 4,000 Abstracts Submitted for Annual Meeting, June 3-7

May 27, 2011

Oncologist Pans Breast Cancer Conference In Russian Heartland

August 19, 1994